Taysha Gene Therapies (TSHA) Consolidated Net Income (2020 - 2026)

Taysha Gene Therapies has disclosed Consolidated Net Income across 7 years of filings, most recently posting -$40.9 million for Q1 2026.

• Consolidated Net Income for Q1 2026 came in at -$40.9 million, down 103.39% year-over-year; the trailing twelve-month figure through Mar 2026 was -$122.1 million (down 48.82% YoY), and the FY2025 annual result was -$101.3 million, down 19.75% from the prior year.
• Consolidated Net Income came in at -$40.9 million for Q1 2026 at Taysha Gene Therapies, down from -$25.4 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$15.0 million in Q4 2023 to a low of -$55.1 million in Q4 2022.
• The 5-year median for Consolidated Net Income is -$24.6 million (2023), against an average of -$27.5 million.
• Across the five-year window, Consolidated Net Income soared 72.69% in 2023 and slumped 103.39% in 2026, its largest moves.
• Taysha Gene Therapies' Consolidated Net Income stood at -$55.1 million in 2022, then soared by 72.69% to -$15.0 million in 2023, then dropped by 21.39% to -$18.3 million in 2024, then tumbled by 39.38% to -$25.4 million in 2025, then tumbled by 60.79% to -$40.9 million in 2026.
• The last three Consolidated Net Income figures came in at -$40.9 million (Q1 2026), -$25.4 million (Q4 2025), and -$30.9 million (Q3 2025), per Business Quant data.